Financial Contrast: SkyAI, Inc. Common Stock (NASDAQ:SKYA) and Capricor Therapeutics (NASDAQ:CAPR)

SkyAI, Inc. Common Stock (NASDAQ:SKYA) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership.

Volatility and Risk

SkyAI, Inc. Common Stock has a beta of 2.04, meaning that its stock price is 104% more volatile than the S&P 500. Comparatively, Capricor Therapeutics has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500.

Valuation & Earnings

This table compares SkyAI, Inc. Common Stock and Capricor Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SkyAI, Inc. Common Stock	$200,000.00	349.14	-$282.50 million	N/A	N/A
Capricor Therapeutics	N/A	N/A	-$105.04 million	($2.32)	-12.30

Capricor Therapeutics has lower revenue, but higher earnings than SkyAI, Inc. Common Stock.

Analyst Ratings

This is a summary of recent ratings for SkyAI, Inc. Common Stock and Capricor Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SkyAI, Inc. Common Stock	1	0	0	0	1.00
Capricor Therapeutics	1	0	9	0	2.80

Capricor Therapeutics has a consensus price target of $48.36, suggesting a potential upside of 69.52%. Given Capricor Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Capricor Therapeutics is more favorable than SkyAI, Inc. Common Stock.

Insider and Institutional Ownership

17.2% of SkyAI, Inc. Common Stock shares are owned by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are owned by institutional investors. 1.2% of SkyAI, Inc. Common Stock shares are owned by company insiders. Comparatively, 9.2% of Capricor Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares SkyAI, Inc. Common Stock and Capricor Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SkyAI, Inc. Common Stock	N/A	-157.91%	-154.40%
Capricor Therapeutics	N/A	-59.27%	-48.65%

Summary

Capricor Therapeutics beats SkyAI, Inc. Common Stock on 8 of the 10 factors compared between the two stocks.

About SkyAI, Inc. Common Stock

SkyAI Inc is developing financial technology platforms focused on users in emerging markets. Its operations include the use of stablecoin-based payment infrastructure and artificial intelligence (AI) technologies to provide financial access, educational tools, and data analysis services for users in Asia, Latin America, and Africa. The company’s platform will utilize the Solana blockchain network to support digital asset and on-chain data applications.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.